After a complex period from 2020 to 2022 due to the pandemic, as for everyone else, we are entering a new stage of our strategic development (2022 – 2027). (2022 – 2027 )
- 2 of our projects are currently in clinical phase: the Stream trial in which 7 patients with retinitis pigmentosa were included by the end of 2022, in collaboration with the Parisian hospital site of the 15/20. Also in clinical phase is the Audiowolf trial, whose main patient inclusion site is the Georges-Pompidou European Hospital. 8 patients with Wolfram syndrome were included by the end of 2022. In early 2023, in order to increase the number of patients in the trial, a second clinical site is being opened in Almeria, Spain. It will allow the inclusion of Spanish and Portuguese patients.
- Acceleration of pre-clinical stages: in order to optimize the chances of projects currently in the preliminary phases in the laboratories of the Institute for Biotherapies (Genethon, AIM and I-Stem) moving into the pre-clinical and clinical phases, the AFM has decided to set up a pre-pipe, i.e. an intermediary airlock in which promising preliminary projects will be integrated and supported. This additional lever should serve as a gas pedal for these projects to lead them to the clinical stages.
- 3D modeling: whether through 3D printing technologies, imaging equipment or I-Stem’s various technological platforms, 3D modeling is developing and showing promising initial results. I-Stem wants its projects to benefit from these technological advances and is setting up an ambitious program for the period 2022-2027 to renew its technological park, either through its own financing, responses to public calls for projects or through partnerships. The first step took place in 2022 with the upgrade of the imaging platform, whose spinning disk microscope can now accommodate 3-dimensional samples.
